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INTRODUCTION 
 
 The development of postpartum fatty liver disease (FLD; i.e., hepatic steatosis or 
lipidosis) in dairy cattle continues to represent a nutrition and management challenge for 
the cow and producer. Of major concern, fatty liver is associated with decreased health 
status, fertility, and lactation performance (Wensing et al., 1997; Bobe et al., 2004). 
Hepatic lipid accrual, especially in the form of triacylglycerol (TAG), may limit 
gluconeogenesis and contribute to inflammation (Rukkwamsuk et al., 1999; Sordillo et 
al., 2009). Moreover, cows with fatty liver are at risk for acquiring other metabolic 
disorders including ketosis and displaced abomasum. For instance, fatty liver cows are 
predisposed to a heightened severity of infectious diseases including mastitis and metritis 
(Hill et al., 1985; Bobe et al., 2004). These outcomes may explain why cows with elevated 
hepatic lipid deposition are prone to infertility and compromised milk production later in 
lactation (Rajala-Schultz et al., 1999; Jorritsma et al., 2000). Herein, the current 
understanding of FLD mechanisms in dairy cows with a focus on very low density 
lipoprotein (VLDL) secretion is reviewed. Evidence is also provided to support the 
hypothesis that rumen-protected choline and docosahexaenoic acid (DHA) co-
supplementation may represent a novel nutritional approach to minimize hepatic lipid 
accretion during the periparturient period.  
 
MECHANISMS OF FATTY LIVER DISEASE 
 
 The advancement of negative energy balance during early lactation promotes 
adipose tissue lipolysis to enhance circulating concentrations of nonesterified fatty acids 
(FA). Dyslipidemia in turn elevates hepatic FA uptake where they are converted to fatty 
acyl-CoA by acyl-CoA synthetase. In the cow, the biochemical mechanisms of hepatic 
steatosis likely involve inadequate mitochondrial β-oxidation of fatty acyl-CoA, enhanced 
TAG esterification, and limited secretion of TAG within VLDL. First, the capacity to 
completely oxidize palmitoyl-CoA to CO2 is not augmented during the transition from 
gestation to lactation (Litherland et al., 2011; McCarthy et al., 2015). In contrast, 
incomplete oxidation to acid-soluble products such as tricarboxylic acid cycle 
intermediates or ketones is maximum during peak lipolytic response (Dann et al., 2006; 
Litherland et al., 2011). In support, plasma lipidomic observations have also revealed 
marked elevations in circulating fatty acylcarnitines during the transition period (Rico et 
al., 2017b). As a consequence of increased hepatic FA uptake and inadequate oxidation, 
fatty acyl-CoA are partitioned towards TAG esterification which is mediated by various 
acyltransferases including glycerol-3-phosphate acyltransferase. In contrast to non-
ruminant experimental models of non-alcoholic FLD in humans (Ferré and Foufelle, 
2010), hepatic de novo lipogenesis of FA does not appear to contribute to TAG deposition 
in dairy cows with FLD (Pullen et al., 1990). Therefore, it is not surprising that observed 
postpartum elevations in liver palmitic (16:0) and oleic (cis-9 18:1) acids in dairy cows 
with FLD mimic observed elevations in plasma FA and the adipose tissue FA profile 
during the immediate postpartum period (Rukkwamsuk et al., 2000). The potential 
implications of these FA on VLDL synthesis and secretion are described below. 
 
 Although hepatic TAG esterification is upregulated during the transition period, 
concomitant elevations in VLDL-TAG secretion could limit the progression of FLD in 
periparturient dairy cows. In humans with simple steatosis and not the advanced 
inflammatory steatohepatitis form of non-alcoholic FLD, the secretion of TAG-containing 
VLDL increases linearly with TAG accrual (Donnelly et al., 2005; Choi and Ginsberg, 
2011). However, the dairy cow has a reduced capacity to export TAG within VLDL from 
liver, relative to non-ruminants (Pullen et al., 1990). Although not a measure of VLDL 
secretion, our untargeted lipidomic approaches have confirmed dramatic reductions in 
circulating plasma TAG (e.g., TAG 60:1, 62:0, and 56:1) and TAG-rich lipoproteins in dairy 
cows transitioning from gestation to lactation (Davis et al., 2018; Saed Samii et al., 
2018a). Assuming VLDL secretion is limited in postpartum dairy cows that develop FLD, 
relative to prepartum cows or clinically-healthy postpartum cows, then one possible 
explanation for limited VLDL export may be limited hepatic apolipoprotein (Apo) B100 
concentrations. Apolipoprotein B100 is required for VLDL assembly and secretion 
(Sundaram and Yao, 2010); however, the mRNA expression of hepatic Apo B100 and 
circulating Apo B100 concentrations decrease as parturition approaches (Bernabucci et 
al., 2004; Bernabucci et al., 2009). Another possibility and focus of this review is a limited 
supply of hepatic phosphatidylcholine (PC), as proposed by Van den Top and coworkers 
(1995). Glycerophospholipids and some sphingolipids (i.e., choline-containing 
sphingomyelin) form a monolayer on the lipoprotein surface surrounding the TAG-rich 
hydrophobic core, and PC is the most abundant glycerophospholipid component of 
lipoprotein surface monolayers. Considerable evidence in biomedical non-ruminant 
experimental models demonstrate that reduced levels of hepatic PC impair the secretion 
of VLDL from liver (Yao and Vance, 1988; Fast and Vance, 1995). To the best of our 
knowledge, no additional evidence exists for any other glycerophospholipid or 
sphingolipid requirement for VLDL secretion including phosphatidylethanolamine (PE) or 
sphingomyelin, respectively. 
 
PHOSPHATIDYLCHOLINE METABOLISM 
 
Glycerophospholipid metabolism is complex. Two major types of 
glycerophospholipids include PC and PE. Of interest, the synthesis of PC involves the 
cytidine diphosphate (CDP)-choline pathway (i.e., Kennedy pathway) and the 
phosphatidylethanolamine N-methyltransferase (PEMT) pathway (Figure 1). Whereas the 
CDP-choline pathway utilizes choline as the key precursor, the PEMT pathway relies on 
the transmethylation cycle and the prerequisite methyl donor S-adenosylmethionine to 
methylate PE. It is generally recognized that PEMT is a liver-specific enzyme (Vance and 
Ridgway, 1988). Although choline may serve as a methyl donor for PE methylation, L-
methionine and betaine are other examples. Importantly, the CDP-choline and PEMT 
pathways appear to work in unison to synthesize PC in liver (Sundler and Akesson, 1975). 
 
Phosphatidylcholine and choline-containing sphingomyelin are the predominant 
phospholipids in human VLDL with far less PE (Wiesner et al., 2009; Dashti et al., 2011). 
Indeed, PC comprises ~70% (mol %) of total phospholipids of rodent plasma VLDL (Agren 
et al., 2005). Earlier work by Fast and Vance (1995) demonstrated that the ratio of total 
PC to PE of nascent particles resembles hepatic organelle membrane phospholipid 
composition. Less clear is the specific types of PC (and maybe PE) that are preferentially 
required for VLDL assembly and secretion. Although attention has focused on the 
importance of choline within PC, we must be cognizant of the complete structure and 
potential functional importance of the two fatty acyl chains. Indeed, VLDL may contain 
hundreds of different types of PC, and early evidence suggests that PC 34:2 (number of 
carbons:number of double bonds; e.g., 16:0/18:2), 34:1 (e.g., 16:0/18:1), and 36:4 (e.g., 
16:0/20:4 or 18:2/18:2) are prevalent on the surface of non-ruminant VLDL (Wiesner et 
al., 2009). The type of PC produced is likely governed by the preferentially utilization of 
specific fatty acids within the CDP-choline or PEMT pathways. For example, PC produced 
by the PEMT pathway are enriched in long-chain polyunsaturated FA (PUFA) including 
omega-6 arachidonic acid (20:4) and omega-3 DHA (DeLong et al., 1999; Pynn et al., 
2011). Indeed, supplementing isolated rat hepatocytes with ethanolamine activates 
PEMT to promote the inclusion of DHA within PC (Samborski et al., 1993), and the 
quantitation of DHA-containing PC is utilized as surrogate measure for PEMT activity (da 
Costa et al., 2011). In contrast, PC synthesized by the CDP-choline pathway are enriched 
in saturated (e.g., 16:0 and 18:0) and unsaturated fatty acids with one or two double 
bonds including oleic and linoleic acids, respectively (DeLong et al., 1999; Pynn et al., 
2011). It is also generally understood that saturated fatty acids are preferentially found at 
the sn-1 position of PC, whereas unsaturated fatty acids typically reside at the sn-2 
position (MacDonald and Sprecher, 1991). 
 
The synthesis and degradation of PC is further complicated by the involvement of 
other intermediary complex lipids including lysophosphatidylcholine (LPC), diacylglycerol, 
and ceramide. Liver LPC acyltransferase reacylates LPC to form PC, whereas PC is 
metabolized by the enzyme phospholipase A2 releasing the fatty acid at the sn-2 position 
to form LPC. In circulation, LPC is a highly-abundant lyso-phospholipid, and LPC 
composition in plasma is a mixture of different species such as 16:0 (40%), 18:2 (20%), 
18:1/18:0 (10–15%) and 20:4 (10%; Ojala et al., 2007). Diacylglycerol is utilized by 
choline phosphotransferase within the CDP-choline pathway, and sphingomyelin 
synthase transfers phosphocholine from PC to ceramide to form sphingomyelin. Although 
not the focus of this review, LPC, diacylglycerol, and ceramide are signaling lipids with 
diverse functions in inflammation, immunity, and insulin-mediated glucose utilization 
(Gräler and Goetzl, 2002; Summers, 2006; Erion and Shulman, 2010). Although the role 
of ceramide in the dairy cow has been extensively evaluated (Rico et al., 2016; Rico et 
al., 2017a; Rico et al., 2018b), the actions of LPC and diacylglycerol are less clear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The complex synthesis and degradation of phosphatidylcholine. CDP, cytidine 
diphosphate; CMP, cytidine monophosphate; CPT, 
cholinephosphotransferase; DAG, diacylglycerol; HCY, homocysteine; 
LPCAT, LPC acyltransferase; PEMT, phosphatidylethanolamine N-
methyltransferase; PLA2, phospholipase A2; SAH, S-adenosylhomocysteine; 
SAM, S-adenosylmethionine. 
 
 
Phosphatidylcholine Biomarkers for Fatty Liver Disease in Dairy Cow 
 
Early evaluation of the bovine plasma lipidome has identified candidate PC 
biomarkers for FLD in postpartum dairy cows (Saed Samii et al., 2017; Saed Samii et al., 
2018a,b). Notably, we have identified multiple plasma PC that decrease during the 
transition from gestation to lactation, which are associated with the development of 
postpartum FLD (Figure 2; Bobe et al., 2004). These include PC 36:6, 32:3, 34:4, 34:6, 
and 37:6. Similar reductions in these PC species were observed in liver biopsied from 
postpartum cows, relative to prepartum (e.g., PC 36:6, Saed Samii et al., 2018a,b). Our 
lab has utilized these lipidomic features as initial targets for the development of nutritional 
therapies aimed at enhancing VLDL secretion in dairy cows. For instance, PC 36:6 may 
contain DHA; therefore, we consider the possibility that DHA supplementation may 
increase hepatic PC 36:6 synthesis and TAG export. These findings are supported by 
observed increases in palmitic acid concentrations within the cellular membrane 
phospholipid layer of hepatocytes with parallel decreases in eicosapentaenoic acid (EPA; 
20:5) and DHA during the periparturient period in dairy cows (Douglas et al., 2007).  
 
 
Figure 2.  Suppressed plasma phosphatidylcholine (PC) levels are associated with fatty 
liver disease in periparturient Holstein dairy cows. Leverage/squared prediction 
error (SPE) plot of 301 complex lipids and their relationship with hepatic lipid 
accumulation. Normalized data represent plasma samples collected from 
periparturient Holstein dairy cows categorized into low (n = 7) or high (n = 7) 
mean (d 5 and 14 postpartum) liver lipid content (5 ± 1 vs. 12 ± 2 % of wet 
weight, respectively). Metabolites in lower right quadrant have high loadings 
and follow the expression pattern of the submodel (i.e., data demonstrate that 
out of 301 metabolites, the suppression of specific PC levels are most 
associated with fatty liver disease). Data were obtained using quadrupole time-
of-flight mass spectrometry. PE = phosphatidylethanoline. 
 
 
DIETARY CHOLINE AND OMEGA-3 FATTY ACID SUPPLEMENTATION 
 
Choline Supplementation  
 
Dietary choline supplementation has been considered a potential nutritional 
therapy to mitigate FLD in dairy cows and humans (Cooke et al., 2007; Guerrerio et al., 
2012; Zenobi et al., 2018). For example, the supplementation of feed-restricted 
nonlactating multiparous Holstein cows during late gestation with rumen-protected 
choline ions (0 to 25.8 g/d) lowered liver TAG deposition in a dose dependent manner 
(Zenobi et al., 2018). To build on their findings, we applied fast protein liquid 
chromatography to demonstrate that this dietary approach increased circulating total TAG 
concentrations in TAG-rich and low density lipoproteins (LDL), and increased circulating 
total phospholipid levels in LDL (Table 1). The mechanisms of these outcomes may 
involve the ability of choline to stimulate hepatic PC synthesis, and thus provide key 
glycerophospholipids for VLDL assembly. Recent findings obtained using bovine 
neonatal hepatocyte cultures suggests that choline chloride supplementation increases 
PC synthesis and VLDL secretion by predominantly activating the CDP-choline pathway 
(Chandler and White, 2017). Although choline may be transformed into betaine to support 
the transmethylation of PE, Chandler and White (2017) observed lower hepatocyte PEMT 
mRNA expression with choline chloride supplementation. Indeed, PC generated by the 
CDP-choline pathway was preferentially detected in VLDL fractions obtained from rodent 
hepatocyte cultures supplemented with radiolabeled choline (Vance and Vance, 1986). It 
is intriguing to postulate whether hepatocyte PEMT pathway activation can be enhanced 
during choline chloride supplementation while in the presence of preferential PE substrate 
containing very long chain PUFA such as DHA (DeLong et al., 1999; Pynn et al., 2011).   
 
Table 1. Effect of increasing intake of ruminally protected choline ions on circulating 
concentrations of triacylglycerol (TAG) in plasma lipoprotein fractions collected 
using fast protein liquid chromatography.1  
1Samples derived from lab of Dr. Charles Staples at the University of Florida following their evaluation of 
feeding increasing amounts of ruminally protected choline (RPC; ReaShure; Balchem Corporation) on 
hepatic health and lactation performance in nonlactating, pregnant Holstein dairy cows in negative energy 
balance (Zenobi et al., 2018). Lipoprotein fractions collected as described by Phipps et al. (2017). 
 
Omega-3 PUFA Supplementation 
 
Omega-3 long-chain PUFA include α-linolenic acid (ALA; 18:3), DHA, 
docosapentaenoic acid (DPA; 22:5), and EPA. Beneficial effects promoted by omega-3 
PUFA are routinely observed in humans and various experimental models (Riediger et 
al., 2009; Kalupahana et al., 2011). These include reductions in circulating TAG in 
patients with hypertriglyceridemia (Mori et al., 2000; Schwellenbach et al., 2006), lower 
plasma levels of pro-inflammatory cytokines such as tumor necrosis factor-α and 
interleukin-1β (Endres et al., 1989; Caughey et al., 1996), and the prevention of 
atherosclerosis and hypertension (Hino et al., 2004; Erkkilä et al., 2006). Although 
uncertain in humans (Poudyal et al., 2011), the dietary intake of fish oil rich in omega-3 
PUFA has an insulin-sensitizing effect in adipose and liver tissues (González-Périz et al., 
2009). In rats fed a 12% canola oil-based diet, improvements in estimated insulin 
sensitivity were observed with the supplementation of EPA and DHA, relative to ALA 
supplementation (Andersen et al., 2008). Improvements in insulin action with EPA and 
DHA supplementation may be due in part to reductions in lipogenesis and heightened FA 
oxidation (Kalupahana et al., 2011). Moreover, omega-3 EPA and DHA serve as 
 TAG-rich lipoprotein fraction Low density lipoprotein fraction 
 Intake of RPC, g/d   P = Intake of RPC, g/d  P = 
Component 0 12.9 25.8 SEM Linear Quadratic 0 12.9 25.8 SEM Linear Quadratic 
TAG,  
mg/dL 
0.97 2.03 1.77 0.22 0.01 0.01 0.74 0.96 0.92 0.08 0.02 0.04 
Cholesterol, 
mg/dL 
0.65 1.04 1.11 0.13 0.01 0.21 34.0 38.5 41.2 3.10 0.09 0.80 
Phospholipid, 
mg/dL 
1.53 1.76 1.66 0.28 0.26 0.09 15.9 19.4 21.6 1.38 0.01 0.69 
substrate for the synthesis of resolvins and protectins which may enhance insulin 
signaling by alleviating chronic inflammation (Serhan and Petasis, 2011). Collectively, 
these benefits associated with dietary DHA and EPA consumption have stimulated 
interest in promoting omega-3 PUFA intake for the prevention of metabolic diseases 
(Kinsella et al., 1990; Mostad et al., 2006). 
 
Omega-3 FA supplementation is also being studied as means to alleviate hepatic 
steatosis in humans. Although not completely defined, the mechanisms of action appear 
to be multifaceted. Omega-3 PUFA are potent peroxisome proliferator-activated receptor-
α activators which in turn stimulates FA oxidation (Pawar and Jump, 2003). Additionally, 
omega-3 PUFA inhibit lipogenesis by downregulating sterol regulatory element-binding 
protein (Xu et al., 1999). Improvements in hepatic oxidative balance and inflammatory 
status are also observed with EPA or DHA supplementation (Li et al., 2005; Ishii et al., 
2009). As described earlier, activation of the hepatic PEMT pathway for PC production 
preferentially utilizes DHA (Samborski et al., 1993; DeLong et al., 1999; Watkins et al., 
2003). Moreover, reduced PEMT activity confers susceptibility to FLD in humans (Song 
et al., 2005). Therefore, DHA supplementation may be a means to selectively activate 
PEMT to promote PC synthesis and thus support the secretion of TAG within VLDL. Such 
an approach may benefit humans (and potentially cows) experiencing reductions in total 
plasma and liver DHA/EPA levels during inflammatory FLD (Puri et al., 2009; Arendt et 
al., 2015). In support, randomized controlled trials have shown reductions in liver fat and 
circulating liver enzymes (i.e., alanine or aspartate aminotransferase) in children and 
adults with advanced non-alcoholic FLD (Nobili et al., 2013; He et al., 2016; Nogueira et 
al., 2016). Unfortunately, we cannot yet discern whether these beneficial outcomes are 
due to enhanced hepatic TAG secretion or because of other aforementioned beneficial 
effects associated with omega-3 FA consumption.  
 
Omega-3 Fatty Acid Supplementation in Dairy Cows 
 
In dairy cows, the effects of dietary supplementation of omega-3 FA including DHA 
on fertility and lactation performance has been extensively studied. Regarding 
reproduction, pregnancy losses are lower in cows fed rolled flaxseed which is rich in ALA, 
relative to cows fed rolled sunflower seed (Ambrose et al., 2006). Moreover, feeding dairy 
cows EPA and DHA may inhibit uterine prostaglandin F2α synthesis, delay regression of 
the corpus luteum, and promote fertility by enhancing embryo survival (Burke et al., 1997; 
Staples et al., 1998). With regard to lactation, heavy emphasis has focused on the ability 
of omega-3 FA supplementation to enrich their concentrations in milk fat (Kitessa et al., 
2004). Such a response is a perceived benefit for the production of functional foods that 
benefit human health (Lock and Bauman, 2004). Indeed, the consumption of omega-3 FA 
in milk may represent a preventive approach for the prevention of type 2 diabetes and 
coronary heart disease (Thorsdottir et al., 2004). Other research has focused on the 
ability of unprotected DHA supplementation to modulate the ruminal microflora and milk 
fat synthesis (Petit et al., 2002; Shingfield et al., 2003; Maia et al., 2007). Our 
understanding of the effects of DHA supplementation on metabolic health in cows is also 
developing. For instance, omega-3 FA may enhance insulin sensitivity in cows (Gingras 
et al., 2007), and elevate circulating insulin and insulin-like growth factor-I during early 
lactation (Heravi Moussavi et al., 2007). Although the effects of omega-3 FA on TAG 
secretion in cows is uncertain, a recent evaluation of dietary rumen-protected DHA 
demonstrated accumulation of DHA in plasma phospholipids in dairy cows (Stamey et al., 
2012).  
 
Effects of Abomasal Infusion of Various Phosphatidylcholine Precursors on Lactation 
Performance, Metabolic Status, and the Hepatic Phosphatidylcholine Lipidome 
 
An interest of our research group is to discover novel dietary approaches that 
maximize hepatic PC synthesis, TAG secretion, and health in dairy cows. In a recent 
proof-of-principle study performed at the Cornell Dairy Research Center, five multiparous 
late lactation Holstein dairy cows were enrolled in a 5 × 5 Latin Square design experiment. 
Cows were continuously abomasally infused for 6 d with emulsion preps containing 
palmitic acid (PA; 98% 16:0; BergaFat F-100 HP; Berg + Schmidt GmbH & Co.), PA + 
choline (50 g of choline ion delivered as choline chloride), PA + L-serine (170 g; 1X 
estimated duodenal flow), behenic acid (BA; 92% 22:0; Berg + Schmidt), or omega-3 FA 
(44% DHA, 0.7% DPA; algae-sourced life’sDHA; DSM Nutritional Products, Inc.). 
Although each cow was infused 301 g of total FA each day (12.54 g/h), infusions were 
balanced for the amount of palmitic acid and glycerol within the omega-3 oil (40 and 19 
g, respectively). Moreover, each emulsion prep contained whey protein, polysorbate 80, 
ethoxyquin, and water. To justify our treatments (Figure 1), palmitic acid is a potent 
inducer of ceramide synthesis (Rico et al., 2016), detected at the sn-1 position of PC 
(MacDonald and Sprecher, 1991), and preferentially utilized by the CDP-choline pathway 
(Vance and Vance, 1986). Choline is the principal substrate for the CDP-choline pathway, 
but also believed to serve as a methyl donor for PEMT activation in a limited capacity. 
We also considered the role of choline in sphingomyelin synthesis and degradation. 
Although a non-essential amino acid, serine may be used for PC and ceramide synthesis 
(Rico et al., 2015a). Behenic acid is a very-long chain saturated FA chosen because of 
its preferential utilization for ceramide synthesis (Rico et al., 2015a; Rico et al., 2018a); 
however, the potential low digestibility of very-long chain FA is a concern. To the best of 
our knowledge our work represents the first intensive evaluation of behenic acid in dairy 
cows. Lastly, our omega-3 FA treatment rich in DHA and DPA was selected because of 
their potential to improve health and PC synthesis via the PEMT pathway (DeLong et al., 
1999; Pynn et al., 2011; Siriwardhana et al., 2012). We are cognizant that our study 
evaluated clinically healthy late lactation cows in positive energy balance, and the 
observed effects may or may not be observed in early lactation cows at risk for FLD. Of 
relevance to our investigation, circulating PC concentrations increase, and plasma 
ceramide concentrations and nutrient partitioning decrease as lactation advances 
(Artegoitia et al., 2014; Rico et al., 2016).  
 
Omega-3 infusion lowered dry matter intake, relative to PA treatment (P < 0.01). 
Milk yields recorded for cows abomasally infused with PA, PA co-infused with serine, or 
BA were comparable (Table 2). These data suggest that BA may also increase circulating 
very-long chain ceramides to support nutrient partitioning (Rico et al., 2015b; Rico et al., 
2017a).  In contrast to our observations in PA cows, omega-3 FA infusion significantly 
decreased (P = 0.03) and PA co-infused with choline tended to lower milk yield (P = 0.08). 
Observed reductions in dry matter intake with DHA treatment were likely the cause 
considering feed efficiency was not modified. This may be due to the ability of omega-3 
FA to promote satiety (Parra et al., 2008). Additionally, a working theory is that both DHA 
and choline lower ceramide levels and improve insulin sensitivity to reduce glucose 
partitioning to the mammary gland. Docosahexaenoic acid supplementation does 
improve bovine insulin sensitivity in vitro (Gingras et al., 2007), and a tendency for lower 
milk yield with high choline intake in mid-lactation cows has been observed (Sharma and 
Erdman, 1988). Such a response may explain the observed tendency for reductions in 
milk yield during late lactation but we argue that this effect would be highly dependent on 
stage of lactation. During early lactation, improvements in insulin sensitivity hold the 
potential to reduce lipolysis and minimize hepatic FA uptake. Indeed, lower levels of 
circulating FA have been observed with choline supplementation during the peripartum 
(Pinotti et al., 2003).  Therefore, clear evidence exists for the improvement in hepatic 
health and milk production during early lactation choline supplementation (Pinotti et al., 
2003; Zahra et al., 2006).  
 
Table 2. Effect of abomasal infusion of palmitic acid (PA; 16:0), PA and choline chloride 
(PA+C), PA and L-serine (PA+S), behenic acid (BA; 22:0), or a mixed omega-
3 oil containing docosahexaenoic and docosapentaenoic acids (DHA/DPA) on 
dry matter intake and milk production in late lactation Holstein dairy cows.1  
 Treatment  
 PA PA+C PA+S BA 
DHA/ 
DPA 
SEM P-value 
Dry matter intake, kg/d 24.4 23.7 22.8 22.9 21.3* 1.61 0.06 
Milk yield, kg/d  29.2 26.2† 28.2 28.5 25.6* 1.72 0.09 
Milk components, kg/d        
  Fat 1.34 1.33 1.18 1.23 0.92 0.15 0.28 
  Protein 0.97 0.82 0.94 0.96 0.93 0.06 0.66 
  Lactose 1.32 1.25 1.30 1.31 1.20 0.08 0.44 
Milk composition, %        
  Fat 4.57 4.32 4.31 4.22* 3.62* 0.14 0.04 
  Protein 3.43 3.29 3.41 3.43 3.65 0.13 0.77 
  Lactose 4.49 4.64† 4.55 4.54 4.69* 0.06 0.09 
Feed efficiency2 1.17 1.10 1.24 1.22 1.25 0.13 0.72 
1In a 5 × 5 Latin Square design experiment, late lactation Holstein dairy cows were continuously abomasally 
infused for 6 d with emulsion preps containing PA (98% 16:0; BergaFat F-100 HP; Berg + Schmidt GmbH 
& Co.), BA (92% 22:0; Berg + Schmidt), PA + Choline (50 g of choline ion delivered as choline chloride), 
PA + Serine (170 g; 1X estimated duodenal flow), or omega-3 FA (44% DHA, 0.7% DPA; life’sDHA; DSM 
Nutritional Products, Inc.). Although each cow was infused 301 g of total FA each day, infusions were 
balanced for the amount of 16:0 and glycerol within the omega-3 oil (40 and 19 g, respectively). Data reflect 
LS Means ± SE for d 5 and 6 of infusion. Relative to PA: *, P < 0.05. †, P < 0.10. 
2Feed efficiency = kg of milk/kg of dry matter intake. 
 
Although milk fat yield was maintained with BA infusion, relative to PA cows, BA 
significantly lowered milk fat content (P = 0.04). Relative to palmitic acid, our data suggest 
that behenic acid digestibility and/or incorporation of behenic acid into milk fat TAG is 
lower. However, omega-3 FA infusion exhibited a far greater suppression in milk fat 
content and a numerical decrease in milk fat yield. These findings are especially intriguing 
because we utilized an abomasal delivery approach; therefore, we consider the effects of 
omega-3 FA on biohydrogenation were negligible. The potent ability of omega-3 FA to 
suppress lipogenesis may be the cause (Xu et al., 1999). It is important to mention that 
DHA dietary supplementation at a much lower level (29 g/d) did not modify milk yield or 
milk fat composition in mid-lactation Holstein cows (Stamey et al., 2012).  
 
The described treatments did not modify circulating glucose or total FA 
concentrations; however, circulating TAG and cholesterol concentrations were greatest 
with PA treatment, whereas the levels of these metabolites were lowest with omega-3 FA 
infusion (unpublished). Such outcomes were expected based on the previously described 
benefits linked with DHA consumption in non-ruminants. We also biochemically mapped 
the bovine hepatic glycerophospholipidome. Profound changes across hundreds of lipids 
were observed with treatment (Figure 3). For instance, DHA was markedly enriched in 
hepatic PC and LPC (e.g., biomarker PC 36:6). Elevations in DHA-containing PC may be 
indicative of enhanced PEMT activity (da Costa et al., 2011). In support, PEMT activation 
prefers PUFA-containing PE (DeLong et al., 1999). Indeed, DHA/DPA infusion robustly 
increased over 100 PC containing more than 3 double bonds, relative to PA cows. In 
contrast, PA infusion significantly increased a similar number of PC containing saturated 
FA or FA containing 3 or less double bonds. These PC may be preferentially synthesized 
by the CDP-choline pathway (Vance and Vance, 1986). We also observed modest 
increases in hepatic PC with choline chloride or L-serine infusion, relative to PA. Although 
some exceptions were observed, omega-3 infusion enhanced the incorporation of PUFA 
(>3 double bonds) into PC, whereas saturated FA feeding, choline, and serine elevated 
hepatic PC containing saturated FA, or FA with 1 to 3 double bonds.  
 
CONCLUSION 
  
 Current evidence supports the ability of dietary rumen-protected choline 
supplementation to enhance TAG disposal in postpartum dairy cows at risk for metabolic 
disease. Our data suggest that the ability of choline to activate the CDP-choline pathway 
to promote PC synthesis may be the cause. However, potential exists to refine nutritional 
practices as a means to optimize liver PC production and VLDL secretion for enhanced 
liver health during the peripartum. Although research should continue to focus on whether 
methyl donor supplementation (e.g., choline and L-methionine) provides added benefit, 
dairy science advancements should determine which dietary FA inhibit or promote hepatic 
PC synthesis and TAG export. Moreover, the identification of methyl donors and fatty 
acids that work in unison to upregulate both the CDP-choline and PEMT pathways to 
maximize PC production and VLDL secretion for the prevention of fatty liver disease 
would represent a paradigm shift in transition cow nutrition. 
 
 
 
Figure 3.  Effect of abomasal infusion of palmitic acid (PA; 16:0), PA and choline chloride 
(PA+C), PA and L-serine (PA+S), behenic acid (BA; 22:0), or a mixed omega-
3 oil containing docosahexaenoic and docosapentaenoic acids (DHA/DPA) on 
select hepatic phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) 
levels in late lactation Holstein dairy cows. Generalized log-transformed 
intensities (Y-axis) derived from time-of-flight mass spectrometry. Samples 
reflect liver biopsied at the end of d 6 of each infusion.  
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